SEC Form 4 · accession 0001193125-26-294561
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher W. Cain
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001590750
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $18.48 | Jul 1, 2026 | A | 32,341 | A | — | Jul 1, 2036 | Common Stock | 32,341 | 32,341 | I |
Explanation of responses
- F1The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
- F2Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.